在癌症治疗中脂-药物结合物:新兴范式和未来方向
Kiran Dudhat1, Harsh Pirojiya2, Krupali Bhalala2
1School of Pharmacy, RK University, Kasturbadham, Rajkot, India. kichupatel@gmail.com.
AAPS PharmSciTech
|July 14, 2025
概括
脂类药物联合体 (PDCs) 通过改善药物输送和降低毒性,提供先进的癌症治疗. 这些新型结合剂提高了治疗效率和精度,有望改善患者的治疗结果.
科学领域:
- 生物医学工程 生物医学工程
- 纳米技术纳米技术
- 在瘤学瘤学.
背景情况:
- 传统的癌症治疗有耐药性,非向毒性和溶解性差等问题.
- 脂-药物合物 (PDC) 将药物分子与脂结合起来,以提高生物相容性和向性.
- PDCs提供增强的药物稳定性,生物可用性和向性输送,减少系统性副作用.
研究的目的:
- 探索脂类药物联合体 (PDCs) 作为癌症治疗中的新方法的潜力.
- 突出PDC如何克服传统癌症治疗的局限性.
- 讨论最近的进展和PDC发展的未来方向.
主要方法:
- PDC利用两性质自组装成纳米载体以控制药物释放.
- 利用通过增强透性和保留 (EPR) 效应的被动准和通过连接体-受体相互作用的积极准.
- 响应刺激的PDCs释放基于瘤微环境因素 (如酸度,酶) 的药物.
主要成果:
- PDCs表现出增强的药物稳定性,生物可用性和有针对性的输送,从而降低了全身毒性.
- 最近的合成策略,包括共价键和生物灵感方法,扩大了PDC的治疗潜力.
- 与纳米技术和基因疗法的整合为精密医学开辟了道路.
结论:
- PDCs代表了癌症治疗的重大进步,提供了更安全,更有效的向治疗.
- 诸如可扩展性和多药耐药性等挑战正在通过人工智能,生物打印和绿色化学来解决.
- 在瘤学之外,PDCs显示出前景,在其他疾病中也有潜在的应用,彻底改变了治疗精度.
相关概念视频
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Phase II Conjugation Reactions: Overview
332
Conjugation, a key component of phase II biotransformation reactions, is a vital process in drug detoxification. It involves transferring endogenous substances like glucuronic acid, sulfate, and glycine to drugs or their metabolites formed in phase I reactions. These conjugation reactions, often catalyzed by specific enzymes, transform potentially harmful metabolites into inactive, water-soluble forms easily excreted in urine or bile. By enhancing polarity and eliminating pharmacological...
332
Cellular Membranes and Drug Transport
980
Drugs must traverse multiple biological barriers, such as multi-layered skin, single-layered intestinal epithelium, and the plasma membrane, to reach their target sites within the body. The plasma membrane, a highly structured composite of phospholipids, carbohydrates, and proteins, is the cell's protective boundary, facilitating selective substance exchange.
Phospholipids arrange themselves into a bilayer, with hydrophilic heads oriented outward and hydrophobic tails facing inward.
Phospholipids arrange themselves into a bilayer, with hydrophilic heads oriented outward and hydrophobic tails facing inward.
980
Prodrugs
3.0K
Prodrugs are a class of pharmaceutical compounds that undergo a biotransformation process within the body to be converted into a pharmacologically active drug. Prodrugs are designed to improve the therapeutic properties of the parent drug, such as enhancing bioavailability, increasing stability, or reducing toxicity. The concept of prodrugs revolves around modifying the chemical structure of the original drug to make it more effective or convenient for administration.
Prodrugs help overcome...
Prodrugs help overcome...
3.0K
Targets for Drug Action: Overview
7.5K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
7.5K


